Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Organogenesis Holdings Inc. Class A Common Stock

ORGO

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Last trade $0.8125
Day change +$0.0094 (+1.17%)
Day range $0.78 – $0.827
Volume 448,757
Market cap $104M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$103.84M
Price / earnings
—
Price / book
0.4×
Price / sales
0.29×
EV / sales
0.27×
EV / EBITDA
-1.54×

Profitability

Earnings per share
-$1.16
Return on assets
-40.7%
Return on equity
-57.14%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.04×
Current ratio
3.32×
Quick ratio
2.76×
Cash ratio
0.45×

Cash flow

Price / cash flow
10.08×
Price / free cash flow
—
Free cash flow
-$64K

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ORGO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$45.46M$43.76M$37.23M$225.61M$150.86M$101.01M$86.69M$126.66M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$45.46M$43.76M$37.23M$225.61M$150.86M$101.01M$86.69M$126.66M
Selling, general and administrative$45.09M$53.97M$65.19M$100.17M$79.74M$73.81M$72.51M$73.86M
Research and development$7.96M$18.3M$15.16M$10.29M$13.22M$10.4M$10.64M$11.53M
Total operating expenses$74.95M$94.75M$106.12M$162.32M$130.14M$113.58M$113.44M$116.44M
Operating income-$29.49M-$50.99M-$68.89M$63.29M$20.73M-$12.58M-$26.75M$10.22M
Interest expense-$61K$0$380K$236K$415K$0$961K$61K
Income before taxes-$29.62M-$50.88M-$68.47M$63.43M$21.16M-$11.83M-$25.78M$10.25M
Income taxes$8K$45.39M-$15.32M$19.73M-$407K-$2.44M-$6.94M$2.58M
Net income-$29.63M-$96.27M-$53.16M$43.7M$21.57M-$9.39M-$18.84M$7.67M
Net income attributable to common shareholders-$32.77M-$99.34M-$53.16M$35.12M$14.53M-$12.2M-$18.84M$5.88M
EBITDA-$25.13M-$46.89M-$59.01M$70.09M$25.6M-$8M-$15.89M$14.67M
Basic earnings per share-$0.25-$0.77-$0.44$0.28$0.11-$0.10-$0.17$0.05
Diluted earnings per share-$0.25-$0.77-$0.44$0.26$0.11-$0.10-$0.17$0.05

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Organogenesis: 3 Key Takeaways for Long-Term Investors

Organogenesis reported Q3 2026 sequential revenue growth of 6% despite industry contraction from Medicare reimbursement policy changes. The company is benefiting from competitor exits and expects $45 million in annual operating expense reductions targeting Q4 profitability. However, the FDA extended the PDUFA target date for its Amnuvx knee osteoarthritis treatment beyond April 24, 2027, due to 18 manufacturing facility inspection items requiring remediation.

GlobeNewswire Inc.

Tissue Engineering Market to Grow at 12.95% CAGR Reaching USD 27.59 Billion by 2031, Driven by Advances in Regenerative Medicine and Biomaterials, Says Mordor Intelligence

The global tissue engineering market is projected to grow from USD 15.01 billion in 2026 to USD 27.59 billion by 2031, driven by advancements in regenerative medicine, biomaterials, and stem cell research. Key growth drivers include increasing demand for regenerative therapies, innovations in 3D bioprinting, rising prevalence of chronic diseases, and expanding applications in orthopedics, skin regeneration, and dental restoration. North America leads the market while Asia-Pacific emerges as a high-growth region.

GlobeNewswire Inc.

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Organogenesis Holdings Inc. announced that its randomized controlled trial of PuraPly®AM plus standard of care versus standard of care alone for non-healing diabetic foot ulcers achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks (p<0.0477). The company plans to publish results in a peer-reviewed journal and believes the findings will support future coverage policies for the product.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vizsla Silver Corp. - VZLA

Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Vizsla Silver Corp., following a security incident at its Mexico project site on January 29, 2026, where ten individuals were taken and operations were temporarily suspended. The incident triggered a 14.87% stock price decline. The firm is also investigating similar claims against Telesat Corporation and Organogenesis Holdings Inc.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations for skin substitute grafts on December 26, 2025. The withdrawal exposes Organogenesis to increased competition from over 300 market participants. The company's stock price fell 10.14% to $5.28 per share on the news.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.